3:20 pm
Welcome and Introduction
Richard P. MacDermott, MD, MACG, FACG and Stephen B. Hanauer, MD, FACG
IBD Clinical Track IA
Moderators: Jean Frederic Colombel, MD and Raymond Cross, MD
3:30 pm
Use and misuse of endoscopy in patients with Crohn’s disease
Douglas C. Wolf, MD, FACG
3:50 pm
Use and misuse of endoscopy in patients with ulcerative colitis
Gary R. Lichtenstein, MD, FACG
4:10 pm
Use and misuse of CT and MR imaging in IBD
David Bruining, MD
4:30 pm
Mimics of IBD
Sunanda V. Kane, MD, FACG
4:50 pm
Panel discussion
5:00 pm
Break
IBD Clinical Track IIA
Moderators: Thomas Ullman, MD, FACG and Bruce E. Sands, MD, FACG
5:20 pm
Thrombosis in IBD
Athos Bousvaros, MD, FACG
5:40 pm
The refractory gluten sensitive enteropathies
Joe Murray, MD, FACG
6:00 pm
Evaluating and treating pain in IBD
Eva Szigethy, MD
6:20 pm
Autoimmune enteropathy and drug induced enteropathy
Joe Murray, MD, FACG
6:40 pm
Panel discussion
6:50 pm
Adjourn
7:00 pm
Welcome reception
8:00 am
Welcome and Introduction
Richard P. MacDermott, MD, MACG, FACG and Stephen B. Hanauer, MD, FACG
IBD Clinical Track IIIA (Parallel with Research Track IIIB)
Moderators: Corey A. Siegel, MD and Gary R. Lichtenstein, MD, FACG
8:10 am
Rick Geswell, President, CCFA
8:30 am
Positioning our recent and future advances in therapies for Crohn’s disease
Speaker Invited
8:50 am
Positioning our recent and future advances in therapies for ulcerative colitis
Stephen B. Hanauer, MD, FACG
9:10 am
Future clinical comparative effectiveness studies: Unanswered questions in the care of IBD patients.
Jean Frederic Colombel, MD
9:30 am
Panel discussion
10:00 am
Break and poster viewing
IBD Clinical Track IVA (Parallel with Research Track IVB)
Moderators: Uma Mahadevan, MD and David Rubin, MD, FACG
10:30 am
Pro: Crohn's colitis patients can be offered an ileoanal pouch
Feza Remzi, MD
10:45 am
Con: Crohn's colitis patients should never be offered an ileoanal pouch
Asher A. Kornbluth, MD
11:00 am
Discussion, synthesis, and consensus
11:10 am
Pro: Asymptomatic ulcerative colitis patients on an immunomodulator, with persistent moderate mucosal inflammation should either add a biologic or switch to a biologic
Speaker Invited
11:25 am
Con: Asymptomatic ulcerative colitis patients on an immunomodulator, with persistent moderate mucosal inflammation should not add a biologic or switch to a biologic
William J. Tremaine, MD, FACG
11:40 am
Discussion, synthesis, and consensus
11:50 am
Pro: An IBD patient on a biologic and/or an immunomodulator, who develops a malignancy (solid tumor, lymphoma or skin cancer), may continue or restart these medications, if needed to treat IBD
Miguel Regueiro, MD, FACG
12:05 pm
Con: An IBD patient on a biologic and/or an immunomodulator, who develops a malignancy (solid tumor, lymphoma or skin cancer), must stop and never restart these medications
Thomas Ullman, MD, FACG
12:20 pm
Discussion, synthesis, and consensus
12:30 pm
Lunch break
IBD Clinical Track VA (Parallel with Research Track VB; Also Parallel with Pediatric IBD Symposium VC)
(45 minutes for each, 15 minutes to move to different session, then another 45 minutes)
2:00 pm
A. Treating the outpatient with severe IBD: Case studies
Corey A. Siegel, MD. and William J. Tremaine, MD, FACG
B. Treatment of extraintestinal manifestations of IBD: Case studies
Robert Burakoff, MD, FACG and Alan C Moss, MD, FACG
C. Prevention and treatment of opportunistic infections in IBD: Case studies
Millie Long, MD and Mark T. Osterman, MD
D. Difficult patient management decisions: Case studies
Doug Wolf, MD, FACG and Speaker Invited
E. Controversies in surveillance for colorectal cancer in IBD: Case studies
Thomas Ullman, MD, FACG and Fernando S. Velayos, MD
2:45 pm
Case-based sessions end: participants have 15 minutes to move to new session
3:00 pm
A. Treating the outpatient with severe IBD: Case studies
Corey A. Siegel, MD. and William J. Tremaine, MD, FACG
B. Treatment of extraintestinal manifestations of IBD: Case studies
Robert Burakoff, MD, FACG and Alan C Moss, MD, FACG
C. Prevention and treatment of opportunistic infections in IBD: Case studies
Millie Long, MD and Mark T. Osterman, MD
D. Difficult patient management decisions: Case studies
Doug Wolf, MD, FACG and Speaker Invited
E. Controversies in surveillance for colorectal cancer in IBD: Case studies
Thomas Ullman, MD, FACG and Fernando S. Velayos, MD
3:45 pm
Break and poster viewing
IBD Clinical Track VIA (Parallel with Research Track VIB; Also Parallel with Pediatric IBD Symposium VIC)
Moderators: Feza Remzi, MD and John Pemberton, MD
4:00 pm
Understanding the techniques of a colectomy with an ostomy and also the techniques of the initial J-pouch surgery (Videos)
Phillip R. Fleshner, MD
4:20 pm
What are the pouch preserving surgical approaches to complications following the initial J-pouch surgery? (Videos)
John Pemberton, MD
4:40 pm
What are the non-surgical approaches to complications following the initial J-pouch surgery? (Videos)
Bo Shen, MD, FACG
5: 00 pm
What are the indications, techniques, and outcomes for pouch revision surgery (Videos)
Feza Remzi, MD
5:20 pm
Panel discussion
5:40 pm
Adjourn
8:00 am
Welcome and Introduction
Richard P. MacDermott, MD, MACG, FACG and Stephen B. Hanauer, MD, FACG
IBD Clinical Track VIIA (Parallel with Research Track VIIB)
Moderators: William J. Tremaine, MD, FACG and Speaker Invited
8:10 am
How often do immunomodulators and/or biologics cause lymphoma and/or cancer, and can we prevent lymphoma and/or cancer in our patients?
James D. Lewis, MD
8:30 am
What are the skin side effects due to immunomodulators and/or biologics?
Jean Frederic Colombel, MD
8:50 am
Infections due to immunomodulators and/or biologics: Identification, prevention and treatment
Corey A. Siegel, MD
9:10 am
Other major side effects due to immunomodulators and/or biologics in our IBD patients
Speaker Invited
9:30 am
Panel discussion
10:00 am
Break and poster viewing
IBD Clinical Track VIIIA (Parallel with Research Track VIIIB)
Moderators: Miguel Regueiro, MD, FACG and Asher A. Kornbluth, MD
10:30 am
A patient with severe Crohn's disease, an ileal stricture and proximal dilation on CTE should have medical therapy first
Uma Mahadevan, MD
10:40 am
A patient with severe Crohn's disease, an ileal stricture and proximal dilation on CTE should have endoscopic therapy first
Bo Shen, MD, FACG
10:50 am
A patient with severe Crohn's disease, an ileal stricture and proximal dilation on CTE should have an ileocolonic resection first
Phillip R. Fleshner, MD
11:00 am
Discussion, synthes5is, and consensus
11:10 am
Pro: Immunomodulators and anti-TNFs must be stopped when a viral, bacterial, or fungal infection occurs
Speaker Invited
11:25 am
Con: Immunomodulators and anti-TNFs may be continued when a viral, bacterial, or fungal infection occurs
Stephen B Hanauer, MD, FACG
11:40 am
Discussion, synthesis, and consensus
11:50 am
Pro: In patients with both CMV and steroid refractory ulcerative colitis, you must treat the ulcerative colitis with biologics, but you do not need to also treat the CMV, because the CMV is an innocent bystander
David Rubin, MD, FACG
12:05 pm
Con: In patients with both CMV and steroid refractory ulcerative colitis, you must treat the CMV, but not the ulcerative colitis, because the refractory colonic inflammation is due to the CMV
David Binion, MD
12:20 pm
Discussion, synthesis, and consensus
12:30 pm
Lunch break
IBD Clinical Track IXA (Parallel with Research Track IXB; Also Parallel with Pediatric IBD Symposium IXC)
(45 minutes for each, 15 minutes to move to different session, then another 45 minutes)
2:00 pm
A. Treating the challenging inpatient with complicated IBD: Case studies
Peter Higgins, MD and Hans Herfarth, MD, FACG
B. How to assess and manage strictures, abscesses, and phlegmons in the complicated Crohn’s disease patient: Case studies
Raymond Cross, MD and David A Schwartz, MD, FACG
C. Common errors in the treatment of IBD: Case studies
David T. Rubin, MD and Gary R. Lichtenstein, MD, FACG
D. Medications in the pregnant patient with a disease flare: Case studies
Uma Mahadevan, MD and Sunanda V. Kane, MD, FACG
E. GI tract infections in IBD: Detection and treatment of Clostridia difficile, CMV and enteric pathogens: Case studies
David Binion, MD and Bruce E. Sands, MD, FACG
2:45 pm
Case-based sessions end: participants have 15 minutes to move to new session
2:00 pm
A. Treating the challenging inpatient with complicated IBD: Case studies
Peter Higgins, MD and Hans Herfarth, MD, FACG
B. How to assess and manage strictures, abscesses, and phlegmons in the complicated Crohn’s disease patient: Case studies
Raymond Cross, MD and David A Schwartz, MD, FACG
C. Common errors in the treatment of IBD: Case studies
David T. Rubin, MD and Gary R. Lichtenstein, MD, FACG
D. Medications in the pregnant patient with a disease flare: Case studies
Uma Mahadevan, MD and Sunanda V. Kane, MD, FACG
E. GI tract infections in IBD: Detection and treatment of Clostridia difficile, CMV and enteric pathogens: Case studies
David Binion, MD and Bruce E. Sands, MD, FACG
3:45 pm
Break and poster viewing
IBD Clinical Track XA (Parallel with Research Track XB; Also Parallel with Pediatric IBD Symposium XC)
Moderators: James D. Lewis, MD and Douglas C. Wolf, MD, FACG
4:00 pm
Treatment of IBD in the elderly
Jean Frederic Colombel, MD
4:20 pm
Treatment of internal and external fistulae in IBD
David A Schwartz, MD, FACG
4:40 pm
After ileo-colonic resection, how can we prevent or delay the recurrence of Crohn’s disease?
Miguel Regueiro, MD, FACG
5:00 pm
Panel discussion
5:20 pm
Adjourn
Check out some of last year’s presentation slides.
Rather have all slidesets in just a few PDF's? Subscribe below and we’ll send them immediately.
Get the latest information as well as last year's slidesets.




